Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Sonia Fox · SciRah

Researcher profile · Semantic Scholar

Sonia Fox

Share profile

Sonia Fox — researcher profile on SciRah

h-index: 7
Works: 33
Citations: 422

Most-cited papers

Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial.
C. Harrison, A. Mead, A. Panchal, Sonia Fox +17 more
2017Blood148 citations Open access
Semantic Scholar
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
C. Harrison, J. Nangalia, R. Boucher, Aimee Jackson +29 more
2023Journal of Clinical Oncology140 citations Open access
Semantic Scholar
The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease
N. Appleby, T. Eyre, M. Cabes, Aimee Jackson +6 more
2019BMC Cancer31 citations Open access
Semantic Scholar
The poor outcome in high molecular risk, hydroxycarbamide resistant/intolerant ET is not ameliorated by ruxolitinib
J. O'Sullivan, A. Hamblin, C. Yap, Sonia Fox +10 more
2019Blood16 citations Open access
Semantic Scholar
MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study
T. Munir, L. Cherrill, N. Webster, S. Dalal +17 more
2022Blood13 citations Open access
Semantic Scholar
Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancers
J. Murray, G. Pratt, Abe Jacob, F. Clark +7 more
2019Contemporary Clinical Trials Communications11 citations Open access
Semantic Scholar
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
Claire N. Harrison, Adam J. Mead, A. Panchal, Sonia Fox +17 more
201711 citations
Semantic Scholar
Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis
Zijian Fang, Giuditta Corbizi Fattori, Thomas McKerrell, R. Boucher +32 more
2023Nature Communications7 citations Open access
Semantic Scholar
S1607 MOLECULAR ANALYSIS IN MAJIC PV CORRELATION WITH CLINICAL ENDPOINTS.
N. Curto-Garcia, Joanna E. Baxter, E. Harris, M. McMullin +5 more
2019HemaSphere6 citations Open access
Semantic Scholar
Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
G. McIlroy, C. Gaskell, Aimee Jackson, Emily Yafai +8 more
2025BMC Cancer5 citations Open access
Semantic Scholar
Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high‐risk acute myeloid leukaemia ineligible for intensive chemotherapy
J. Loke, M. Metzner, R. Boucher, Aimee Jackson +9 more
2021British Journal of Haematology5 citations Open access
Semantic Scholar
Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial
G. McIlroy, Siân Lax, C. Gaskell, Aimee Jackson +11 more
2024BMC Cancer4 citations Open access
Semantic Scholar
Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
C. Harrison, J. Nangalia, R. Boucher, Aimee Jackson +28 more
2022Blood4 citations Open access
Semantic Scholar
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial
R. Dillon, Shanna Maycock, Aimee Jackson, Sonia Fox +13 more
2022BMC Cancer4 citations Open access
Semantic Scholar
Heterogeneous genetic and non‐genetic mechanisms contribute to response and resistance to azacitidine monotherapy
Vasiliki Symeonidou, M. Metzner, B. Usukhbayar, Aimee Jackson +3 more
2022eJHaem4 citations Open access
Semantic Scholar
RUXOLITINIB COMPARED WITH BEST AVAILABLE THERAPY FOR ESSENTIAL THROMBOCYTHAEMIA PATIENTS RESISTANT OR INTOLERANT TO HYDROXYCARBAMIDE IN MAJIC - AN INVESTIGATOR LEAD RANDOMIZED TRIAL
C. Harrison, A. Mead, A. Panchal, Sonia Fox +12 more
20164 citations
Semantic Scholar
The SF3B1 K666 Hotspot Mutation Confers Unfavourable Disease Risk across Major Myeloid Neoplasm Subgroups
Jennifer O. Sullivan, Amy Wood, S. Wen, A. Hamblin +6 more
2023Blood3 citations
Semantic Scholar
Vorinostat Does Not Improve Outcome in Patients with Acute Myeloid Leukemia and High Risk Myelodysplasia Treated with Azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial
C. Craddock, Aimee E. Houlton, P. Ferguson, M. Raghavan +11 more
20163 citations
Semantic Scholar
Assessment and Validation of the EQ-5D Among a Population of Myeloproliferative Neoplasm Patients
R. Scherber, S. Knapper, Sonia Fox, H. Kosiorek +14 more
20152 citations
Semantic Scholar
Prospective Cohort Study of Non-COVID Infection in Patients with AML/MDS Undergoing Treatment: Implications for Practice
Justin Loke, C. Gaskell, Emily Yafai, Sonia Fox +22 more
2024Blood1 citations
Semantic Scholar
Treatment of the blood cancer polycythemia vera with ruxolitinib in the MAJIC-PV study: a plain language summary
Claire N. Harrison, Sonia Fox, R. Boucher, M. McMullin +1 more
2024Future Oncology1 citations Open access
Semantic Scholar
Defective T‐cell response to COVID‐19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes
J. Loke, V. Upasani, C. Gaskell, Sonia Fox +30 more
2023British Journal of Haematology1 citations Open access
Semantic Scholar
Trial re-investment to build better research for better impact.
Thomas A. Fox, G. Horne, C. Craddock, G. Cook +5 more
2019The Lancet1 citations Open access
Semantic Scholar
A phase IIa study of the anti-PD-L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL-T trial.
M. Ahearne, Matthew A. Timmins, C. Gaskell, Aimee Jackson +25 more
2026British Journal of Haematology0 citations Open access
Semantic Scholar
The REFRACT trial: implementation of Bayesian power priors in a randomised, sequential phase II adaptive platform trial
C. Gaskell, K. Linton, M. Bishton, G. McIlroy +7 more
2025BMC Medical Research Methodology0 citations Open access
Semantic Scholar
Promise: Investigation into the Combination of a Potent Beti with Ruxolitinib in Patients with High or Intermediate-2 Risk Myelofibrosis Not Receiving an Adequate Response with Ruxolitinib Alone
A. Mead, C. Harrison, Brian J. P. Huntly, B. Psaila +6 more
2023Blood0 citations Open access
Semantic Scholar
3031 – CHROMOTHRIPSIS AND LEUKEMIC TRANSFORMATION IN MPN
C. Brierley, B. Yip, G. Orlando, H. Goyal +25 more
2023Experimental Hematology0 citations Open access
Semantic Scholar
Exploring Genotype:Phenotype Correlations at Baseline and at One Year for ET and PV Patients in the Majic Study
C. Saha, Carolyn Mead-Harvey, A. Mead, R. Boucher +15 more
2021Blood0 citations
Semantic Scholar
Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration Program
Ting-Lo-Ke Ching, C. Gaskell, Sonia Fox, R. Fletcher +34 more
2021Blood0 citations Open access
Semantic Scholar
Correlation of Quality of Life between Treatment Outcomes in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Polycythemia Vera
Isaak Ailts, Carolyn Mead-Harvey, A. Mead, Sonia Fox +15 more
2021Blood0 citations Open access
Semantic Scholar
Molecular Characterisation of Participants in the Phazar Trial Reveals Prognostic Impact of Mutations in Advanced-Phase-MPN
C. Brierley, A. Rodriguez-Meira, M. Bashton, A. Hamblin +13 more
20200 citations Open access
Semantic Scholar
Longitudinal Mutational Analysis in Hydroxycarbamide-Resistant/Intolerant Essential Thrombocythemia Treated on the Majic-ET Study
Jennifer O'Sullivan, A. Hamblin, A. Panchal, C. Yap +10 more
2018Blood0 citations
Semantic Scholar
Correlation Between Treatment Outcomes, Baseline Characteristics and Molecular Responses in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Essential Thrombocythemia
C. Harrison, A. Mead, Sonia Fox, A. Panchal +18 more
20160 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. McMullin×19
Invite
M. McMullin — researcher profile on SciRah
A. Mead×16
Invite
A. Mead — researcher profile on SciRah
R. Boucher×16
Invite
R. Boucher — researcher profile on SciRah
Aimee Jackson×14
Invite
Aimee Jackson — researcher profile on SciRah

×13

Invite

C. Harrison — researcher profile on SciRah

Invite

S. Knapper — researcher profile on SciRah

Invite

J. Coppell — researcher profile on SciRah

Invite

C. Gaskell — researcher profile on SciRah

Invite

C. Yap — researcher profile on SciRah

Invite

J. Ewing — researcher profile on SciRah

Invite

A. Dueck — researcher profile on SciRah

Invite

M. Drummond — researcher profile on SciRah